British investigators argue that many of the studies supporting drug treatment of osteopenia understate the side effects, overstate the benefits, involve potential conflicts of interest, and base efficacy claims on reductions in relative, rather than absolute, risk for fractures.
British investigators argue that many of the studies supporting drug treatment of osteopenia understate the side effects, overstate the benefits, involve potential conflicts of interest, and base efficacy claims on reductions in relative, rather than absolute, risk for fractures.
They cite one raloxifene trial that touts a 75% reduction in relative risk of fracture, which translates into only a 0.9% reduction in absolute risk. They also mention four studies, one each involving alendronate, raloxifene, risedronate, and strontium ranelate, that indicate anywhere from 0.9% to 8.6% absolute risk exists over 3 to 5 years in control patients. That means that anywhere from 133 to 270 women with preosteoporosis (women "at risk for being at risk") need to be treated with drugs for 3 years to prevent a single fracture in one of them.
The World Health Organization is currently developing an absolute fracture risk algorithm to assist practitioners with managing women categorized as having osteopenia. In the meantime, the practitioners remind us that the number 1 risk factor for fracture is falls, not low bone mineral density, and that we should work on preventing the former as much as we do the latter.
Unraveling preeclampsia: Insights into heterogeneity and intravascular inflammation
April 22nd 2024A recent study delved into the intricate clusters of term preeclampsia, shedding light on its diverse manifestations and the pivotal role of intravascular inflammation, paving the way for improved classification and management strategies.
Read More
Personalized opioid protocol for cesarean deliveries: Reduced prescriptions reported
April 19th 2024A recent suggests that implementing a personalized opioid prescription protocol significantly reduces total morphine milligram equivalents and the number of opioid tablets prescribed at discharge following cesarean delivery.
Read More
Long-term mortality risks for women with adverse pregnancy outcomes
April 19th 2024A recent study revealed that women who experience major adverse pregnancy outcomes face heightened long-term mortality risks, shedding light on the need for comprehensive understanding and preventative measures in women's health.
Read More